<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2182-5173</journal-id>
<journal-title><![CDATA[Revista Portuguesa de Medicina Geral e Familiar]]></journal-title>
<abbrev-journal-title><![CDATA[Rev Port Med Geral Fam]]></abbrev-journal-title>
<issn>2182-5173</issn>
<publisher>
<publisher-name><![CDATA[Associação Portuguesa de Medicina Geral e Familiar]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2182-51732020000600503</article-id>
<article-id pub-id-type="doi">10.32385/rpmgf.v36i6.12629</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Statin-associated necrotizing myopathy: a rare etiology]]></article-title>
<article-title xml:lang="pt"><![CDATA[Miopatia necrotizante associada a estatinas: uma etiologia rara]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Moita]]></surname>
<given-names><![CDATA[Catarina Ferreira]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Mendonça]]></surname>
<given-names><![CDATA[Alexandra]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Leite]]></surname>
<given-names><![CDATA[Raquel Baptista]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Vasconcellos]]></surname>
<given-names><![CDATA[Ana Paes de]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Dantas]]></surname>
<given-names><![CDATA[Ana]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,USF S. Martinho de Alcabideche  ]]></institution>
<addr-line><![CDATA[Cascais ]]></addr-line>
<country>Portugal</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,USF S. Martinho de Alcabideche  ]]></institution>
<addr-line><![CDATA[Cascais ]]></addr-line>
<country>Portugal</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2020</year>
</pub-date>
<volume>36</volume>
<numero>6</numero>
<fpage>503</fpage>
<lpage>506</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_arttext&amp;pid=S2182-51732020000600503&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_abstract&amp;pid=S2182-51732020000600503&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_pdf&amp;pid=S2182-51732020000600503&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Introduction:  Necrotizing autoimmune myopathy is a rare entity characterized by proximal muscle weakness, elevated creatine kinase levels, potential autoantibody presence, and myofiber necrosis with reduced or absent inflammation.  Case description:  We report the case of a 72-year-old female with a 3-week-history of asthenia, increasing proximal tetraparesis, without pain, fever, or other symptoms, and elevated creatine kinase levels. Previous history was remarkable for dyslipidemia controlled with statin therapy. A muscular biopsy was performed, leading to the diagnosis of necrotizing myopathy. A body computed tomography (CT) scan was normal. Corticotherapy was initiated with progressive clinical and analytical improvement.  Discussion:  This case depicts an uncommon and underdiagnosed pathology which may be associated with statin treatment or cancer, that requires an early diagnosis and close follow-up for better clinical outcomes.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Resumo  Introdução:  A miopatia necrotizante autoimune constitui uma entidade rara, caracterizada por diminuição da força muscular proximal, níveis séricos elevados de creatina cinase, eventual presença de autoanticorpos e necrose muscular com inflamação reduzida ou ausente.  Descrição do caso:  Apresenta-se o caso de uma mulher de 72 anos com uma história de astenia e tetraparesia proximal com três semanas de evolução, sem dor, febre ou outra sintomatologia e níveis séricos elevados de creatina cinase. Como antecedentes relevantes apresentava dislipidemia controlada com estatina. Foi realizada biópsia muscular, tendo sido estabelecido o diagnóstico de miopatia necrotizante. A tomografia computadorizada toraco-abdomino-pélvica (TC-TAP) não mostrou alterações relevantes. Iniciou corticoterapia com melhoria clínica e analítica progressiva.  Comentário:  Este caso relata uma patologia incomum e subdiagnosticada que pode estar associada a tratamento com estatina ou neoplasias, requerendo um diagnóstico célere e um acompanhamento rigoroso para melhores resultados clínicos.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Myositis]]></kwd>
<kwd lng="en"><![CDATA[Rhabdomyolysis]]></kwd>
<kwd lng="en"><![CDATA[Hydroxymethylglutaryl-CoA reductase inhibitors]]></kwd>
<kwd lng="en"><![CDATA[Autoantibodies.]]></kwd>
<kwd lng="pt"><![CDATA[Miosite]]></kwd>
<kwd lng="pt"><![CDATA[Rabdomiólise]]></kwd>
<kwd lng="pt"><![CDATA[Inibidores hidroximetilglutaril-CoA reductase]]></kwd>
<kwd lng="pt"><![CDATA[Autoanticorpos.]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Senécal]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Raynauld]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Troyanov]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Editorial a new classification of adult autoimmune myositis]]></article-title>
<source><![CDATA[Arthritis Rheumatol]]></source>
<year>2017</year>
<volume>69</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>878-84</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Allenbach]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Mammen]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[Benveniste]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Stenzel]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[224th ENMC International Workshop clinico-sero-pathological classification of immune-mediated necrotizing myopathies, Zandvoort, The Netherlands, 14-16 October 2016]]></article-title>
<source><![CDATA[Neuromuscul Disord]]></source>
<year>2018</year>
<volume>28</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>87-99</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pinal-Fernandez]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Parks]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Werner]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Albayda]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Paik]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Danoff]]></surname>
<given-names><![CDATA[SK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Longitudinal course of disease in a large cohort of myositis patients with autoantibodies recognizing the signal recognition particle]]></article-title>
<source><![CDATA[Arthritis Care Res]]></source>
<year>2017</year>
<volume>69</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>263-70</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Okada]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Mimori]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Mukai]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Kashiwagi]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Hardin]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Characterization of human autoantibodies that selectively precipitate the 7SL RNA component of the signal recognition particle]]></article-title>
<source><![CDATA[J Immunol]]></source>
<year>1987</year>
<volume>138</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>3219-23</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mammen]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[Chung]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Christopher-Stine]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Rosen]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Rosen]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Doering]]></surname>
<given-names><![CDATA[KR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy]]></article-title>
<source><![CDATA[Arthritis Rheum]]></source>
<year>2011</year>
<volume>63</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>713-21</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Suzuki]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Ohta]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Shimizu]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Hayashi]]></surname>
<given-names><![CDATA[YK]]></given-names>
</name>
<name>
<surname><![CDATA[Nishino]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Anti-signal recognition particle myopathy in the first decade of life]]></article-title>
<source><![CDATA[Pediatr Neurol]]></source>
<year>2011</year>
<volume>45</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>114-6</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Svensson]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Arkema]]></surname>
<given-names><![CDATA[EV]]></given-names>
</name>
<name>
<surname><![CDATA[Lundberg]]></surname>
<given-names><![CDATA[IE]]></given-names>
</name>
<name>
<surname><![CDATA[Holmqvist]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Incidence and prevalence of idiopathic inflammatory myopathies in Sweden a nationwide population-based study]]></article-title>
<source><![CDATA[Rheumatol]]></source>
<year>2017</year>
<volume>56</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>802-10</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dobloug]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Garen]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Bitter]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Stjärne]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Stenseth]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Grøvle]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalence and clinical characteristics of adult polymyositis and dermatomyositis data from a large and unselected Norwegian cohort]]></article-title>
<source><![CDATA[Ann Rheum Dis]]></source>
<year>2015</year>
<volume>74</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1551-6</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ohnuki]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Suzuki]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Shiina]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Uruha]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Watanabe]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Suzuki]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[HLA-DRB1 alleles in immune-mediated necrotizing myopathy]]></article-title>
<source><![CDATA[Neurology]]></source>
<year>2016</year>
<volume>87</volume>
<numero>18</numero>
<issue>18</issue>
<page-range>1954-5</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Allenbach]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Drouot]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Rigolet]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Charuel]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Jouen]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Romero]]></surname>
<given-names><![CDATA[NB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Anti-HMGCR autoantibodies in European patients with autoimmune necrotizing myopathies inconstant exposure to statin]]></article-title>
<source><![CDATA[Medicine]]></source>
<year>2014</year>
<volume>93</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>150-7</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Watanabe]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Suzuki]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Nishimura]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Murata]]></surname>
<given-names><![CDATA[KY]]></given-names>
</name>
<name>
<surname><![CDATA[Kurashige]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Ikawa]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Statins and myotoxic effects associated with anti-3-hydroxy-3-methylglutaryl-coenzyme a reductase autoantibodies an observational study in Japan]]></article-title>
<source><![CDATA[Medicine]]></source>
<year>2015</year>
<volume>94</volume>
<numero>4</numero>
<issue>4</issue>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mohassel]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Mammen]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Anti-HMGCR myopathy]]></article-title>
<source><![CDATA[J Neuromuscul Dis]]></source>
<year>2018</year>
<volume>5</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>11-20</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Allenbach]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Keraen]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Bouvier]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Jooste]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Champtiaux]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Hervier]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[High risk of cancer in autoimmune necrotizing myopathies usefulness of myositis specific antibody]]></article-title>
<source><![CDATA[Brain]]></source>
<year>2016</year>
<volume>139</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>2131-5</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Watanabe]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Uruha]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Suzuki]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Nakahara]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Hamanaka]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Takayama]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy]]></article-title>
<source><![CDATA[J Neurol Neurosurg Psychiatry]]></source>
<year>2016</year>
<volume>87</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1038-44</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Suzuki]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Nishikawa]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Kuwana]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Nishimura]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Watanabe]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Nakahara]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Inflammatory myopathy with anti-signal recognition particle antibodies case series of 100 patients]]></article-title>
<source><![CDATA[Orphanet J Rare Dis]]></source>
<year>2015</year>
<volume>10</volume>
<page-range>61</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tiniakou]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Pinal-Fernandez]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Lloyd]]></surname>
<given-names><![CDATA[TE]]></given-names>
</name>
<name>
<surname><![CDATA[Albayda]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Paik]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Werner]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[More severe disease and slower recovery in younger patients with anti-3-hydroxy-3-methylglutarylcoenzyme A reductase-associated autoimmune myopathy]]></article-title>
<source><![CDATA[Rheumatology]]></source>
<year>2017</year>
<volume>56</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>787-94</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pinal-Fernandez]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Casal-Dominguez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Mammen]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Immune-mediated necrotizing myopathy]]></article-title>
<source><![CDATA[Curr Rheumatol Rep]]></source>
<year>2018</year>
<volume>20</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>21</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Leff]]></surname>
<given-names><![CDATA[RL]]></given-names>
</name>
<name>
<surname><![CDATA[Burgess]]></surname>
<given-names><![CDATA[SH]]></given-names>
</name>
<name>
<surname><![CDATA[Miller]]></surname>
<given-names><![CDATA[FW]]></given-names>
</name>
<name>
<surname><![CDATA[Love]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Targoff]]></surname>
<given-names><![CDATA[IN]]></given-names>
</name>
<name>
<surname><![CDATA[Dalakas]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Distinct seasonal patterns in the onset of adult idiopathic inflammatory myopathy in patients with anti-Jo-1 and anti-signal recognition particle autoantibodies]]></article-title>
<source><![CDATA[Arthritis Rheum]]></source>
<year>1991</year>
<volume>34</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1391-6</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Valiyil]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Casciola-Rosen]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Hong]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Mammen]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Christopher-Stine]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies a case series]]></article-title>
<source><![CDATA[Arthritis Care Res]]></source>
<year>2010</year>
<volume>62</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1328-34</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mammen]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[Tiniakou]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Intravenous immune globulin for statin-triggered autoimmune myopathy]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2015</year>
<volume>373</volume>
<numero>17</numero>
<issue>17</issue>
<page-range>1680-2</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
